CASE STUDY
The Client:
An artificial intelligence-powered synthetic biology company operating at the cutting edge of biotechnology where machine learning algorithms accelerate drug discovery, protein engineering, and therapeutic development, the firm represents the convergence of computational power and biological innovation. Developing proprietary platforms that enable pharmaceutical partners to design and optimize biological compounds with unprecedented speed and precision, the company had established strategic relationships with major drug developers and positioned itself for substantial milestone payments tied to customer drug submissions and regulatory approvals. As a pre-revenue or minimal-revenue biotechnology company preparing for a public offering, the business faced the classic challenge of balancing aggressive growth requiring significant capital investment in specialized lab and testing equipment against the imperative to preserve equity ownership and avoid dilutive fundraising in a challenging capital markets environment where biotech valuations had compressed significantly.
The Challenge:
The company needed to preserve cash within a dramatically challenged market for raising capital, where biotech IPO valuations had declined and venture capital investors had grown increasingly selective and demanding of higher ownership stakes for growth capital. Despite having very little current revenue, the business was on the cusp of recognizing substantial milestone payments from customer drug submissions—future cash flows that were virtually certain but not yet realized, creating a timing mismatch between equipment investment needs and available liquidity. Traditional equipment lenders were uncomfortable financing a pre-revenue biotech company regardless of the quality of its technology platform or the caliber of its pharmaceutical partnerships, viewing the revenue profile as prohibitively risky. The company faced a strategic dilemma: either raise dilutive equity capital at depressed valuations to fund necessary lab equipment purchases, significantly reducing founder and early investor ownership ahead of the IPO, or delay critical equipment investments and risk falling behind in platform development and customer deliverables precisely when competitive positioning and execution momentum were essential to IPO success.
Solution:
First National Capital recognized that beneath the minimal current revenue lay a fundamentally strong biotechnology platform with blue-chip pharmaceutical partnerships, substantial near-term milestone payments, and a clear path to IPO that simply required patient capital willing to look beyond traditional revenue metrics. FNC approved $8 million in financing for various lab and testing equipment essential to platform development and customer deliverables, understanding that preserving equity ahead of the public offering was critical to maximizing value for founders and early investors. First National structured an innovative solution that replenished cash from prior equipment purchases through a sale-leaseback, immediately restoring liquidity that had been depleted by earlier capital deployments, while simultaneously establishing a CAPEX line of credit to fund all future equipment needs without requiring repeated financing negotiations or equity dilution. By understanding the unique nature of the synthetic biology industry—where significant value creation precedes substantial revenue generation and where milestone-based business models create lumpy cash flows—FNC leveraged the company’s strong balance sheet, pharmaceutical partnerships, and IPO trajectory to structure a deal that preserved critical equity ownership while ensuring the business had access to the specialized equipment necessary for continued platform development. This financing partnership enabled the company to maintain its aggressive development timeline, preserve equity value ahead of the public offering, and demonstrate to IPO investors that the business had established sophisticated capital relationships beyond traditional venture funding.
It All Begins With A Conversation
We listen. We live out-of-the-box. We solve problems. And we get deals done. Let’s do this.
